The US Food and Drug Administration (FDA) has approved France-based Advanced Accelerator Applications' radioactive drug, Lutathera (lutetium Lu 177 dotatate), intended for the treatment of gastroenteropancreatic
neuroendocrine tumours, it was reported yesterday.
has received US Food and Drug Administration approval of its new drug application for Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic
neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors, in adults.
Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic
Neuroendocrine Tumors: Review of Recent Literature.
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic
Prognostic factors of long-term outcome in gastroenteropancreatic
Expression pattern of CDX2, estrogen and progesterone receptors in primary gastroenteropancreatic
neuroendocrine tumors and metastases.
Ipsen and Teijin Pharma Limited, the core company of the Teijin Groups healthcare business, today announced that Teijin Pharma has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsens subcutaneous drug Somatuline (lanreotide) for the treatment of gastroenteropancreatic
neuroendocrine tumors (GEP NET).
methylation pattern in gastroenteropancreatic
Somatostatin gene expression in gastroenteropancreatic
system during postnatal development of rats.
Guidelines for the management of gastroenteropancreatic
neuroendocrine (including carcinoid) tumours (NETs).
Tumours with high expression of receptors: gastroenteropancreatic
Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic
neuroendocrine tumors," International Journal of Clinical and Experimental Pathology, vol.